More articles from Current Drug Therapy

  • Antiobesity drug therapy: An individualized and comprehensive approach
    Yael Mauer, MD, MPH, Marcie Parker, PharmD, BCACP and Sangeeta R. Kashyap, MD
    Cleveland Clinic Journal of Medicine August 2021, 88 (8) 440-448; DOI: https://doi.org/10.3949/ccjm.88a.20080

    As part of a comprehensive plan, these drugs can provide lasting obesity control and additional health benefits, including decreased cardiovascular risk.

  • Prescribing testosterone and DHEA: The role of androgens in women
    Taryn Smith, MD, NCMP and Pelin Batur, MD, FACP, NCMP
    Cleveland Clinic Journal of Medicine January 2021, 88 (1) 35-43; DOI: https://doi.org/10.3949/ccjm.88a.20030

    Androgens play an important physiologic role and can promote sexual health.

  • The role of SGLT-2 inhibitors in managing type 2 diabetes
    Yumiko Tsushima, MD, M. Cecilia Lansang, MD, MPH and Vinni Makin, MBBS, MD, FACE
    Cleveland Clinic Journal of Medicine January 2021, 88 (1) 47-58; DOI: https://doi.org/10.3949/ccjm.88a.20088

    These drugs improve glycemic control and offer cardiovascular and metabolic benefits.

  • CGRP antagonists for decreasing migraine frequency: New options, long overdue
    Julia Bucklan, DO and Zubair Ahmed, MD
    Cleveland Clinic Journal of Medicine April 2020, 87 (4) 211-218; DOI: https://doi.org/10.3949/ccjm.87a.19048

    CGRP drugs are an exciting frontier, but migraine management is still a combination of lifestyle changes plus treatment.

  • ACE inhibitors and ARBs: Managing potassium and renal function
    Tasnim Momoniat, MBCHB, MRCP (UK), Duha Ilyas, MBBS, MRCP (UK) and Sunil Bhandari, MBCHB, FRCP, PhD, M CLIN EDU, FHEA
    Cleveland Clinic Journal of Medicine September 2019, 86 (9) 601-607; DOI: https://doi.org/10.3949/ccjm.86a.18024

    Concern about hyperkalemia and a decline in renal function has led to underuse of these drugs.

  • Diabetes management: Beyond hemoglobin A1c
    Vinni Makin, MBBS, MD, FACE and M. Cecilia Lansang, MD, MPH
    Cleveland Clinic Journal of Medicine September 2019, 86 (9) 595-600; DOI: https://doi.org/10.3949/ccjm.86a.18031

    Other factors include cardiovascular benefit, weight control, hypoglycemia risk, and cost.

  • Hydroxychloroquine: An old drug with new relevance
    Eugen Alexander Shippey, MD, Vanya D. Wagler, DO, FACP, FACR and Angelique N. Collamer, MD, FACP, FACR
    Cleveland Clinic Journal of Medicine June 2018, 85 (6) 459-467; DOI: https://doi.org/10.3949/ccjm.85a.17034

    This antimalarial drug is now approved to treat discoid lupus, systemic lupus erythematosus, and rheumatoid arthritis.

  • Pharmacotherapy for obesity: What you need to know
    Sophie Bersoux, MD, MPH, Tina H. Byun, MD, Swarna S. Chaliki, MD and Kenneth G. Poole, MD, MBA
    Cleveland Clinic Journal of Medicine December 2017, 84 (12) 951-958; DOI: https://doi.org/10.3949/ccjm.84a.16094

    Weight-loss drugs are not magic pills, but they can help when used along with diet, exercise, and other lifestyle changes.

  • Dual antiplatelet therapy for acute coronary syndromes: How long to continue?
    Dual antiplatelet therapy for acute coronary syndromes: How long to continue?
    Meghana Halkar, MD and A. Michael Lincoff, MD
    Cleveland Clinic Journal of Medicine September 2016, 83 (9) 675-688; DOI: https://doi.org/10.3949/ccjm.83a.15092

    After drug-eluting stent placement, at least 12 months of dual antiplatelet therapy is recommended. Would longer be better?

  • Ceftaroline fosamil: A super-cephalosporin?
    Riane J. Ghamrawi, PharmD, BCPS, Elizabeth Neuner, PharmD and Susan J. Rehm, MD
    Cleveland Clinic Journal of Medicine July 2015, 82 (7) 437-444; DOI: https://doi.org/10.3949/ccjm.82a.14105

    Ceftaroline fosamil is the first beta-lactam with clinically useful activity against methicillin-resistant Staphylococcus aureus.

Pages